Parenchymal lung involvement in adult-onset Still disease
A STROBE-compliant case series and literature review

Mathieu Gerfaud-Valentin, MDab,c,e, Vincent Cottin, MD, PhDbd,e, Yvan Jamilloux, MDab,c, Amaud Hot, MD, PhDbd,e,f, Agathe Gaillard-Coadon, MDab,c, Isabelle Durieu, MD, PhDbc,f,g, Christiane Broussolle, MDab,c, Jean Iwaz, PhDab,c, Mathieu Gerfaud-Valentin, MDab,c, Vincent Cottin, MD, PhDbd,e, Yvan Jamilloux, MDab,c, Amaud Hot, MD, PhDbd,e,f, Agathe Gaillard-Coadon, MDab,c, Isabelle Durieu, MD, PhDbc,f,g, Christiane Broussolle, MDab,c, Jean Iwaz, PhDab,c

Abstract
Parenchymal lung involvement (PLI) in adult-onset Still’s disease (AOSD) has seldom, if ever, been studied. We examine here retrospective cohort AOSD cases and present a review of the literature (1971–2014) on AOSD-related PLI cases.

Patients with PLI were identified in 57 AOSD cases. For inclusion, the patients had to fulfill Yamaguchi or Fautrel classification criteria, show respiratory symptoms, and have imaging evidence of pulmonary involvement, and data allowing exclusion of infectious, cardiogenic, toxic, or iatrogenic cause of PLI should be available. This AOSD+PLI group was compared with a control group (non-PLI-complicated AOSD cases from the same cohort).

AOSD+PLI was found in 3 out of the 57 patients with AOSD (5.3%) and the literature mentioned 27 patients. Among these 30 AOSD+PLI cases, 12 presented an acute respiratory distress syndrome (ARDS) and the remaining 18 another PLI. In the latter, a nonspecific interstitial pneumonia computed tomography pattern prevailed in the lower lobes, pulmonary function tests showed a restrictive lung function, the alveolar differential cell count was neutrophilic in half of the cases, and the histological findings were consistent with bronchiolitis and nonspecific interstitial pneumonia. Corticosteroids were fully effective in all but 3 patients. Ten out of 12 ARDS cases occurred during the first year of the disease course. All ARDS-complicated AOSD cases received corticosteroids with favorable outcomes in 10 (2 deceased). Most PLIs occurred during the systemic onset of AOSD.

PLI may occur in 5% of AOSDs, of which ARDS is the most severe. Very often, corticosteroids are efficient in controlling this complication.

Abbreviations: ACPA = anticitrullinated protein autoantibody, ANA = antinuclear autoantibody, ANCA = antineutrophil cytoplasmic autoantibody, AOSD = adult-onset Still disease, ARDS = acute respiratory distress syndrome, BAL = bronchoalveolar lavage, CRP = C-reactive protein, CT = computed tomography, DLCO = diffusing capacity of the lung for carbon monoxide, ESR = erythrocyte sedimentation rate, HRCT = high-resolution computed tomography, IL = interleukin, PFT = pulmonary function test, PLI = parenchymal lung involvement, reHLH = reactive hemophagocytic lymphohistiocytosis, VC = vital capacity.

Keywords: acute respiratory distress syndrome, adult-onset Still disease, hemophagocytic lymphohistiocytosis, interstitial lung disease

1. Introduction
Adult-onset Still disease (AOSD) is a rare complex autoimmune syndrome of unknown etiology. Its main clinical features are high spiking fever, evanescent salmon-pink rash, polyarthritis, sore throat, and lymphadenopathy.[1] However, the spectrum of clinical manifestations and complications of this entity are very wide.[2,3] The usual laboratory findings are disease-unspecific; they include elevated polymorphonuclear neutrophil count, high C-reactive protein (CRP) level, and high liver enzyme levels.[1,2,3] The combination of a 5-fold increase in serum ferritin and a glycosylated ferritin level ≤ 20% led to 93% specificity in AOSD diagnosis; nevertheless, in daily practice, this diagnosis remains one of exclusion.[4] According to recent pathophysiological findings, cohort studies, and clinical trials, 2 phenotypes of AOSD may be distinguished: a systemic pattern (monocyclic or polycyclic AOSD) and a chronic articular pattern. Both should be treated with corticosteroids and methotrexate as first disease-modifying antirheumatic drugs. In cases of refractory AOSD, more efficient treatments would be the blockade of interleukin-1 (IL-1) pathway in the systemic pattern and the blockade of IL-6 pathway in the chronic articular pattern.[1,3,5] To date, few studies have focused on the visceral complications of AOSD: reactive hemophagocytic lymphohistiocytosis (reHLH)
is the most frequent life-threatening complication of systemic AOSD, but myocarditis was also mentioned and well defined.\(^6\)–\(^8\) Besides, no study has focused yet on parenchymal lung involvement (PLI): pleuritis was mentioned in 10% to 50% of the main retrospective AOSD series,\(^3\),\(^9\),\(^10\) but other pulmonary involvement events have been reported only as isolated cases; none of the main AOSD cohorts has reported on PLI.\(^10\)

Here, we study PLI in AOSD by reporting on 3 original cases from a cohort of 57 patients with AOSD and reviewing additional cases from the medical literature.\(^11\)

2. Patients and methods

Cases of AOSD with PLI were identified in a retrospective cohort of 57 patients with AOSD seen in our institution (University Hospitals of Lyon, France) between 1998 and 2010.\(^11\) In addition, we carried out a computer-assisted search for publications on AOSD with PLI in English and French exclusively. The search was made in PubMed (National Library of Medicine, Bethesda, MD), from 1971 (when AOSD was first described) to June 2014, using string ‘(‘Adult onset Still disease’ or ‘Adult onset Still’s disease’) AND (‘lung involvement’ or ‘pulmonary involvement’ or ‘interstitial lung disease’ or ‘acute respiratory distress syndrome’ or ‘respiratory failure’ or ‘pneumonitis’ or ‘pneumonia’ or ‘lung’). The reference lists of all retrieved articles were also examined for references not identified in the initial search and duplicate publications were excluded.

Patients were included in the present study whenever they fulfilled the following criteria: confirmed AOSD diagnosis (Yamaguchi or Fautrel classification criteria for AOSD)\(^12\),\(^13\); age >16 years at PLI onset; presence of respiratory symptoms (cough, dyspnea, abnormalities on auscultation, etc.); at least a chest radiography or high-resolution computed tomography (HRCT) showing parenchymal lung infiltrates; and available data that allow excluding infectious causes (sputum culture, bronchoalveolar lavage [BAL] fluid analysis, blood culture, serology, antibiotic treatment failure), cardiogenic causes (brain natriuretic peptide dosage, transthoracic ultrasonography), and toxic or iatrogenic causes (with special attention to methotrexate orTNF inhibitors failures). All other patients were excluded.

The clinical features, laboratory findings, pulmonary function test (PFT) results, BAL results, imaging results, therapeutic strategies, and outcomes were collected and analyzed independently by 2 investigators (AGC and MGV) using a standardized form. In case of mismatch, a third investigator (PS) was asked to complete the form. Finally, AOSD-associated PLI cases in the cohort were reviewed and confirmed by a multidisciplinary team that included interstitial lung disease specialists.

Patients with interstitial lung disease were classified according to the HRCT patterns and the international classification of idiopathic interstitial pneumonias. The latter distinguishes major idiopathic interstitial pneumonias (idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, respiratory bronchiolitis interstitial lung disease, desquamative interstitial pneumonia, cryptogenic organizing pneumonia, and acute interstitial pneumonia) from rare idiopathic interstitial pneumonias (lymphoid interstitial pneumonia and fibroblastoid) and unclassifiable idiopathic interstitial pneumonias.\(^14\) For “acute respiratory distress syndrome (ARDS),” we adopted Berlin definition.\(^13\)

Bone marrow biopsies were performed in all atypical cases to rule out neoplastic or preneoplastic conditions that share common symptoms with AOSD (especially malignant lymphoma).

Here, AOSD + PLI cases from the cohort together with the cases found in the literature formed the “AOSD + PLI group.” This group was compared with a “control group” of 54 patients with AOSD without PLI from the cohort. Between-group differences regarding a list of relevant variables were tested using Fisher exact test for categorical variables or Kruskal–Wallis test for continuous variables. A P value <0.05 was required for statistical significance. The analyses were performed with R software (R Foundation for Statistical Computing, Vienna, Austria; http://cran.r-project.org/).

According to the current French Legislation (Loi Huriet-Sérusclat 88–1138, December 20, 1988, and its subsequent amendments, text available at http://www.chu-toulouse.fr/IMG/pdf/loihurstier.pdf), an observational study that does not change routine management of patients does not need to be declared or submitted to the opinion of a research ethics board.

3. Results

3.1. Case series

Among the 57 patients with AOSD (27 men and 30 women), the mean follow-up was 8.4 years (median: 6 years), the median age at AOSD diagnosis was 36 years (range: 16–75), and the clinical and laboratory data were comparable with previous literature data.\(^11\) Most of the patients (75%) were followed up in internal medicine or rheumatology departments. The systemic onset of the disease was more prevalent than in previous series and one-third of the patients exhibited a life-threatening complication. In this series, 3 out of 57 patients fulfilled the inclusion criteria for AOSD + PLI (cases 1–3 in Tables 1 and 2). Thus, in this AOSD series, the prevalence of AOSD + PLI was 5.3%.

3.1.1. Case 1. In September 2007, a 47-year-old smoking man was admitted to a general hospital because of a first onset of high spiking fever (40°C), chills, sore throat, headache, and chest pain. Chest radiography and transthoracic ultrasonography performed in the emergency unit yielded arguments for pleuritis and pericarditis. The total-body HRCT showed interstitial and alveolar hyperdensities in the right lower lobe together with atelectasis in the middle lobe. Laboratory data were the following: CRP—382 mg/L, high erythrocyte sedimentation rate (ESR)—51 mm/h, leukocytes—25,000/mm³, neutrophils—22,500/mm³, and procalcitonin—<0.1 ng/mL. Serum ferritin was 473 µg/L (norm: 20–300 µg/L). Liver function tests, lactate dehydrogenase, and β2-microglobulin were in the normal range. Pleural fluid analysis showed a sterile exudate with 60% nonaltered neutrophils. The possibility of an infectious disease was carefully investigated with blood cultures, sputum cultures, tests for Legionella and pneumococcal urinary antigens, and serologies; these were sterile or negative. The searches for rheumatoid factors, anticitrullinated protein autoantibodies (ACPAs), antinuclear autoantibodies (ANAs), and antineutrophil cytoplasmic autoantibodies (ANCAs) were negative. A bone marrow aspiration and a bone marrow biopsy revealed a reactive inflammatory pattern without lymphoma infiltrate or hemophagocytosis.

The PFT showed a restrictive lung function. Bronchoscopy was normal and the BAL examination was consistent with a neutrophilic alveolitis (2,000,000 cells/mL, 60% neutrophils). The transbronchial lung biopsy showed a lymphocytic bronchiolitis together with macrophagic alveolitis related to smoking.

After the failure of an empirical antibiotic therapy (amoxicillin and spiramycin), the patient was administered prednisone 1 mg/kg/d, which led to a rapid improvement in clinical,
biological, and radiological symptoms. Then, a progressive decrease of steroid dose was initiated. At 15 mg prednisone/d, the symptoms relapsed (pleuroperticarditis, arthralgia, and sore throat). The laboratory data became comparable to those found at the onset of the disease, but glycosylated ferritin was significantly decreased (19%). Thus, the diagnostic criteria for AOSD were fulfilled and the lung involvement was deemed AOSD-linked. Corticosteroid dose was increased and colchicine, intravenous immunoglobulins, and methotrexate were successively given to taper prednisone dosages. The disease relapsed 3 times between 2007 and 2011. Finally, remission was obtained with prednisone 5 mg/d and methotrexate 20 mg/wk. The patient is currently asymptomatic and HRCT and PFT are totally normalized.

3.1.2. Case 2. A 64-year-old man was referred to our center in 2002. He had no particular medical history and was not a smoker. He had suffered, since 1999, from an intermittent biopsy-proven neutrophilic dermatitis considered as an atypical Sweet syndrome. He had during the last few months a transient rash, an intermittent fever (38–39°C), sweats, a 6-kg weight loss, sore throat, dysphonia, cough with mucopurulent sputum, arthralgia, and lymphadenopathy. He has been successfully treated with antibiotics and corticosteroids.

The HRCT showed bilateral confluent hyperdensities consistent with peribronchovascular micronodules, ground-glass hyperdensities, and alveolar condensation, together with 2 excavated lesions in the left lower lobe. This was associated with a mild bilateral pleural effusion and mediastinal lymphadenopathy.

The laboratory data were the following: CRP—158 mg/L; high ESR; procalcitonin—<0.1 ng/mL; hemoglobin—95 g/L; leucocytes—5500/mm³ (64% neutrophils); platelets—220,000/mm³; serum ferritin—1432 μg/L; and 29% glycosylated ferritin. As in case 1, serology, blood culture, and BAL culture excluded infection. The bone marrow biopsy revealed a nonspecific inflammatory reaction without hemophagocytosis or malignant lymphoma infiltration. The searches for rheumatoid factors, ACPA, ANCA, and ANA were negative.

The PFT showed the following: vital capacity (VC)—2.71 L (71%); forced expiratory volume in 1 second (FEV1)—78%; and diffusion capacity of the lung for carbon monoxide (DLCO)—85%. Bronchoscopy showed an erosive bronchitis and bronchial biopsies revealed a nongranulomatous ulcerated bronchitis. The BAL content was 486 cells/mm³ with 95% neutrophils.

An empirical antibiotic therapy (ceftriaxone and spiramycin) was not beneficial. Because AOSD was suspected, a 1 mg/kg/d prednisone treatment was started. This treatment proved highly efficient; all the above-described symptoms regressed. Chest computed tomography (CT) reversed to normal after 2 months of treatment. However, the patient developed a steroid dependence at 15 mg/d prednisone. Colchicine and then hydroxychloroquine was added as steroid-sparing treatment. During the following 3 years, 5 relapses of subacute interstitial lung disease occurred when corticosteroids were tapered below 10 mg/d but resolved with higher dosage. Three years later, the pulmonary functional tests were recovered: VC—2.71 L (71%); forced expiratory volume in 1 second (FEV1)—78%; and DLCO/alveolar volume: 82%. During the following years, the lung involvement did not relapse but the patient developed a chronic reHHL. He was started on intravenous immunoglobulins and azathioprine. Infliximab 5 mg/kg was also introduced in 2007 but did not allow controlling the disease; the patient remained steroid-dependent at 20 mg/d prednisone. In 2011, the patient died from myocardial infarction.

3.1.3. Case 3. In April 2006, a 42-year-old man with a history of heroin abuse and ongoing substitution treatment, cured hepatitis C, and left iliac osteitis presented with cough and dyspnea. A 5-day treatment with amoxicillin–clavulanate and prednisone was inefficient. Two days later, he exhibited fever (39°C), polyarthralgia, and myalgia. A CT showed bilateral alveolar and mediastinal lymphadenopathy together with a right segmental atelectasis. Finally, the progression was favorable after switching for pristinamycin.

In June 2006, the patient was referred to our center after a 7-kg weight loss during the last 2 months, recurrent fever, cough, and New York Heart Association-IV dyspnea. The clinical examination revealed mild edema of the lower limbs, hepatopatogenic reflux, oligoarthritis of the knees and left wrist, transient nonpruritic rash of the trunk, and cervical lymphadenopathy. The laboratory findings were the following: CRP—250 mg/L; high ESR; leucocytes—19,230/mm³; neutrophils—17,210/mm³; fibrinogen—7 g/L; prothrombin time—52%; creatinine—60 μmol/L; elevated transaminases (3 times the normal values); serum ferritin—19,000 μg/L; and glycosylated ferritin—<5%. The bone marrow biopsy was consistent with an inflammatory reactive hyperplasia without hemophagocytosis or lymphomaous infiltrate.

The HRCT showed bilateral pleural and pericardial effusion with mediastinal infra- and centimetric lymph nodes, parenchymal consolidation in the middle lobe and lingula with bronchogram, and passive atelectasis of the lower lobes. The thoracic ultrasonography confirmed the right-chamber-compressing circumferential pericardial effusion, which was treated by surgical pericardial drainage.

The BAL was hypercellular with 90% neutrophils. The standard cultures and acid-fast bacilli smear and culture were negative. Serology (including HIV testing) and blood cultures ruled out the possibility of infectious disease. The searches for rheumatoid factors, cryoglobulin, ACPA, ANCA, and ANA were negative.

Pleuritis disappeared and atelectasis improved after treatment of the tamponade. Then, another chest CT revealed reticular hyperdensities and sepal thickenings. The PFTs could not be performed. Despite a broad-spectrum antibiotic treatment, the patient remained febrile and developed a myocarditis. As the presentation became evocative of complicated AOSD, an intravenous corticosteroid pulse therapy (1 mg/kg/d) was started. The patient became afibrile within 2 days and exhibited a significant clinical improvement, which persisted after shifting to oral corticosteroids.

A control chest HRCT showed regressions of pleural effusion, atelectasis, alveolo-intertstitial, and lymphadenopathy. After an 18-month follow-up, the outcome was favorable allowing tapering corticosteroids. The patient was then lost to follow-up.

3.2. Literature cases

The literature search identified 41 cases of AOSD+PLI in 37 citations. Fourteen cases were excluded because of the following: insufficient data (n=4)[16–19]; non-English or non-French language (n=5)[20–24]; impossibility to rule out an infectious or iatrogenic origin of PLI (n=3)[25–27]; uncertain AOSD diagnosis (n=1)[28]; and isolated atelectasis (n=1)[29]. Finally, 27 cases from the literature were kept for analysis (cases 4–30 in Tables 1 and 2). The AOSD+PLI group amounted thus to 30 patients[30–32] (Fig. 1).
3.3. Description of the AOSD+PLI group

Among the 30 patients with AOSD+PLI, 12 suffered from ARDS. This subgroup is described separately (Fig. 1).

3.3.1. Patients with non-ARDS PLI.

Eighteen patients (9 males and 9 females) had AOSD + PLI without ARDS (Table 1). The mean age at AOSD onset in this group was 33.8 years (range: 3–67) and the mean age at PLI onset was 36.6 years (range: 20–67). Respiratory symptoms occurred at onset of AOSD in 9 patients: during the first year of the disease course in 2 patients but later in the remaining 7 (range: 14–204 months). The recurrent respiratory symptoms were cough (13/18, 72%), dyspnea (8/18, 44%), and chest pain (4/18, 22%). Basal crackles (rales) were reported in 5 cases.

The chest x-ray and HRCT revealed unilateral or bilateral interstitial hyperdensities in 13/18 cases (72%) and alveolar hyperdensities in 9/18 cases (50%) with air bronchogram in 6/18 cases (33%). The sites of the lesions were specified in 14 cases: the main site was the lower lobes (11/14), whereas the upper and the middle lobe were less affected (3 and 2/14, respectively). The main HRCT patterns were the following: nonspecific interstitial pneumonia (3 cases), organizing pneumonia (4 cases), and unclassified interstitial lung disease (6 cases). These infiltrates were associated with a pleural effusion in 8 patients and mediastinal lymphadenomegaly in 4 others. Furthermore, 2 patients presented a pneumomediastinum, 2 others atelectasis, 1 excavated nodules, and 1 bronchiectasis.

PFTs were performed in only 7/18 patients. These tests showed a restrictive lung function in 6 cases and an isolated decreased DLCO in 1 case. Patient 8 presented an associated obstructive lung function (Table 1).

BAL analysis results were available in 8/18 patients. The differential cell count profile was mainly neutrophilic (>15% neutrophils in half of the cases, 4/8), lymphocytic, mixed, macrophagic, and hemorrhagic (1 case of each profile).

Six transbronchial lung biopsies and 1 surgical lung biopsy were performed. The histological findings were consistent with bronchitis or bronchiolitis in 2 cases, nonspecific interstitial pneumonia in 2 cases, and organized pneumonia in 3 cases. A nonspecific interstitial fibrosis was found in 3 patients.

All but 1 patient were treated with corticosteroids, 3 received additional intravenous immunoglobulins, and 1 patient was treated with salicylates only. The outcome of the pulmonary involvement was favorable within a few days or weeks in 14/18 cases, whereas 3 patients kept significant PFT abnormalities or dyspnea after 2 years,[30] 4 months,[34] and 10 years.[35] The outcomes of the other cases were not specified. No patient died from respiratory failure.

In 14 cases, the systemic or chronic pattern of the underlying AOSD could be identified. PLI occurred in both patterns but mainly in the former: 11/14 PLIs in systemic AOSD (4 monocyclic AOSD and 7 polycyclic AOSD) versus 3/14 PLIs in chronic articular AOSD.

Finally, in 5 patients, PLI was associated with other well-documented AOSD complications: myocarditis, tamponade, severe systemic inflammation response syndrome, and reHLH (2 cases). In 2 other patients, the association with reHLH was not investigated[33,40] (Table 2).

3.3.2. Patients with ARDS.

Among the 12 patients with ARDS, 7 were women (Tables 1 and 2, cases 19–30). The mean age at AOSD onset was 35 years (range: 9–74) and the mean age at ARDS onset was 37.5 years (range: 20–74). ARDS occurred at the onset of the disease in 7 cases, during the first year after diagnosis in 3 other cases, and 10 and 20 years later in the remaining 2 cases. All these patients but 1 (11/12) suffered initially from dyspnea; 5 presented with cough and 5 others with crackles at lung auscultation.

In these 12 cases, imaging findings were consistent with ARDS (bilateral interstitial and alveolar hyperdensities). A pleural effusion was reported in 5 cases and mediastinal lymphadenopathy in 1 case. According to the worst PaO2/FiO2 ratio, 2 patients suffered from mild ARDS (200 < PaO2/FiO2 ≤ 300) and 10 from moderate to severe ARDS. The formula of BAL was available in 1 case and was neutrophilic. A lung biopsy was performed in 1 case and was consistent with an organizing pneumonia associated with diffuse alveolar damage.[48]
| Case | First author | Time from AOSD onset (age) | Respiratory symptoms and signs | Imaging data/HRCT pattern | PFT data | Bronchoscopy and BAL findings | Pulmonary histology | Subset of PLI | Specific treatment | Respiratory outcome |
|------|--------------|---------------------------|-------------------------------|--------------------------|----------|----------------------------|----------------|------------|------------------|-------------------|
| 1    | This series  | Initial picture (47)     | Chest pain                    | CT, right lower middle lobe alveolar interstitial, subpleural honeycombing, pleural effusion | BAL: 2000/mm³, 60% PMNs, 25% lymphocytes | TBLB: lymphocytic bronchiolitis | Bronchitis, inflammatory alveolar, interstitial | Prednisone, IVIG | Favorable            |
| 2    | This series  | 3 yr (64)                 | Cough                         | CT, interstitial, ground-glass, and alveolar hyperdensities, subpleural honeycombing | BAL: 486 leukocytes/mm³, 95% PMNs, sterile | TBLB: non granulomatous ulcerated bronchi | Bronchitis and unspecified ILD | Prednisone | Favorable            |
| 3    | This series  | Initial picture (43)     | Dyspnea, cough, crackle-rules | CT, alveolar hyperdensities, air bronchogram, reticular infiltrates, lymphocytic bronchiolitis | BAL: 1500 leukocytes/mm³, 90% PMNs, sterile | NP | Unclassifiable ILD | Methylprednisolone | Favorable            |
| 4    | Corbett[30] | 14 mo (21)                | Dyspnea, cough, left basal rules | CT, left lower lobe infiltrate | RLF: FEV1 64%; FVC 68%; RLF: 2.71L (71%); FEV1/VC 78%; DCO 85% | BAL: 2000/mm³, 60% PMNs, 25% lymphocytes | Bronchitis, inflammatory alveolar | Prednisone, IVIG, Methylprednisolone | Favorable            |
| 5    | Cantor[31]  | 13 yr (34)                | Dyspnea, pulmonary rales      | CT, alveolar hyperdensities, air bronchogram, reticular infiltrates, lymphocytic bronchiolitis | BAL: 2000/mm³, 60% PMNs, 25% lymphocytes | TBLB: non specific interstitial inflammation with fibrosis | Bronchitis and unspecified ILD | Prednisone | Persistent severe restrictive defect |
| 6    | Corbett[30] | 6 mo (36)                 | Cough                         | CT, hilar lymphangiectasis, CT, lower lobes alveolar and interstitial infiltrates | BAL: 1500 leukocytes/mm³, 90% PMNs, sterile | LP | Unclassifiable ILD | Methylprednisolone | Favorable            |
| 7    | Yoshimura[32] | 17 yr (30)              | Dyspnea, tachypnea, basal crackle-rules | CT, diffuse interstitial infiltrates, subpleural honeycombing | RLF: VC 50% L, 25% DCO 20%, PaO2 77 mmHg, PaCO2 37 mmHg | NP | ILD (UIP or NSIP) | Methylprednisolone, IVIG | NA |
| 8    | Dikensoy[34] | 6 yr (21)                 | Dyspnea, cough, expectoration, cyanosis, subcutaneous emphysema, bilateral rales | CT, diffuse bronchiectasis, air trapping signs accentuated on expiratory CT | BAL: 2500 leukocytes/mm³, 95% PMNs, 25% lymphocytes, 11% monocytosis, 8% macrophages | NP | ILD (UIP or NSIP) | Methylprednisolone, IVIG | Favorable            |
| 9    | Tsuruki[35]  | Initial picture (45)     | Cough                         | CT, alveolar hyperdensities, air bronchogram, bilateral interstitial infiltrates in lower lobes | BAL: 1500 leukocytes/mm³, 95% PMNs, sterile | NP | Organizing pneumonia | Prednisone | Favorable, mild persistent RLF |
| 10   | Hijikata[36] | 1 mo (67)                 | Cough                         | CT, alveolar hyperdensities in right upper lobe | BAL: 2000/mm³, 60% PMNs, 25% lymphocytes | NP | Organizing pneumonia | Prednisone | Favorable (within 3 wk) |
| 11   | Sato[37]    | 5 yr (28)                 | Dyspnea, cough                | CT, alveolar hyperdensities, air bronchogram, bilateral interstitial infiltrates in right upper lobe | BAL: 2000/mm³, 60% PMNs, sterile | NP | Diffuse alveolar hemorrhage | Methylprednisolone | Favorable            |
| 12   | Nie[38]     | Initial picture (39)     | Cough, chest pain, tachycardia | CT, bilateral alveolar infiltrates, air bronchogram, bilateral interstitial infiltrates in lower lobes | BAL: 2000/mm³, 60% PMNs, sterile | NP | Unclassifiable ILD | Methylprednisolone | Favorable (within 5 d) |
| 13   | Nie[38]     | Initial picture (39)     | Cough, chest pain, tachycardia | CT, bilateral alveolar infiltrates, air bronchogram, bilateral interstitial infiltrates in lower lobes | BAL: 2000/mm³, 60% PMNs, sterile | NP | Unclassifiable ILD | Methylprednisolone | Favorable (within 7 d) |
| 14   | Sato[39]    | Initial picture (52)     | Cough, chest pain, tachycardia | CT, alveolar hyperdensities and air bronchogram in right upper lobe | BAL: 2000/mm³, 60% PMNs, sterile | NP | Organizing pneumonia | Prednisone | Favorable            |
| 15   | Ito Yakou[40]| 15 mo (64)              | Dyspnea, cough, chest pain    | CT, pleural effusion, CT, bronchiectasis with confluent pleural thickening | BAL: 2000/mm³, 60% PMNs, sterile | NP | Bronchitis, inflammatory stenotic bronchiectasis, BAL, NP | Prednisone | Favorable (within 1 wk) |

(continued)
### Table 1 (continued).

| Case | First author | Time from AOSD onset (age) | Respiratory symptoms and signs | Imaging data/HRCT pattern | PFT data | Bronchoscopy and BAL findings | Pulmonary histology | Subset of PLI | Specific treatment | Respiratory outcome |
|------|--------------|---------------------------|-------------------------------|---------------------------|----------|-------------------------------|-------------------|--------------|-------------------|-------------------|
| 16   | Ak [41]      | Initial picture (24)      | Cough                         | CXR: right lower and middle lobe infiltrate, small pleural effusion | NP       | NP                            | NP                | Unclassified ILD | Prednisone       | Favorable         |
| 17   | Fuji [42]    | Initial picture (64)      | NA                            | CT: reticulonodular and ground glass hyperdensities, in lower lobes | NP       | NP                            | NP                | Unclassified ILD | Methylprednisolone | Favorable         |
| 18   | Ghosh [43]   | Initial picture (30)      | Dyspnea, cough, tachypnea, crackle rales | CT: patchy infiltrates in left upper lobe, CT: interstitial and alveolar hyperdensities in the left upper lobe, air bronchogram | NP       | BAL sterile                    | TSLB: interstitial dense lymphoplasmacytic infiltrates with focal organizing pattern | Organizing pneumonia | Methylprednisolone | Favorable         |
| 19   | Pedersen [44] | Initial picture (33)      | Dyspnea                       | CT: bilateral interstitial infiltrates | NP       | NP                            | NP                | ARDS | Methylprednisolone | Favorable         |
| 20   | Paizsán [45] | Initial picture (20)      | Cough, dyspnea                | CT: bilateral interstitial infiltrates; CT: bilateral alveolar hyperdensities, mediastinal lymphangiography | NP       | BAL, Streptococcus pneumonia (amplifier-associated pneumonitis) | NP                | ARDS | Methylprednisolone | Favorable         |
| 21   | Iglesias [46] | Initial picture (20)      | Dyspnea, tachypnea, cough, crackle rales | CT: bilateral alveolar infiltrates; CT: bilateral alveolar infiltrates | NP       | BAL, sterile                   | NP                | ARDS | Methylprednisolone | Favorable         |
| 22   | Carr [47]    | Initial picture (37)      | Dyspnea                       | CT: interstitial and alveolar hyperdensities | NP       | NP                            | NP                | ARDS | Methylprednisolone | Favorable         |
| 23   | Stolec [48]  | Initial picture (74)      | Dyspnea                       | CT: interstitial and alveolar hyperdensities | NP       | BAL, sterile                   | NP                | ARDS, Organizing pneumonia | Methylprednisolone, MG | Death            |
| 24   | Suhaimi [49] | Initial picture (30)      | Pleuritic cough; Dyspnea       | CT: interstitial and alveolar infiltrates with air bronchogram | Pao2/Fio2 85 mm Hg (RePEEP 10 cm H2O) | Bronchoscopy normal | BAL, sterile | ARDS | Methylprednisolone, Methotrexate | Favorable within <1 wk |
| 25   | Hagiyama [50] | Initial picture (24)      | Dyspnea                       | CT: interstitial and alveolar infiltrates with air bronchogram | Pao2/Fio2 60 mm Hg | Bronchoscopy normal | BAL, sterile | ARDS | Methylprednisolone, Prednisone, Cyclophosphamide (700 mg on first day) | Favorable (14 d) |
| 26   | Hagiyama [51] | Initial picture (24)      | Dyspnea                       | CT: bilateral infiltrates with air bronchogram | Pao2/Fio2 41 mm Hg | Bronchoscopy normal | BAL, sterile | ARDS | Methylprednisolone | Favorable (12 d) |
| 27   | Biran [2005] | Initial picture (14 d)    | Dyspnea, tachypnea, cough     | CT: diffuse pulmonary infiltrates with air bronchogram | Pao2/Fio2 220 mm Hg | Bronchoscopy normal | BAL, normocellular, 30% PMN, sterile | Methylprednisolone, Prednisone | Favorable (within 2 d) | |
| 28   | Biran [2005] | Initial picture (69)      | Dyspnea, tachypnea, cough     | CT: diffuse pulmonary infiltrates with air bronchogram | Pao2/Fio2 233 mm Hg | Bronchoscopy normal | BAL, normocellular, sterile | Pleural fluid sterile exudate | Methylprednisolone, Prednisone | Favorable (within 3 d) |
| 29   | Biran [2005] | Initial picture (43)      | Dyspnea, tachypnea, cough     | CT: diffuse pulmonary infiltrates with air bronchogram | Pao2/Fio2 278, and then worsened | Bronchoscopy normal | BAL, sterile | ARDS | Methylprednisolone, Prednisone, Infliximab | Favorable (within 2 d) |
| 30   | Oua [52]     | Initial picture (30)      | Dyspnea, cough, chest pain, crackle rales | CT: diffuse pulmonary infiltrates with air bronchogram | Pao2/Fio2 278, and then worsened | Bronchoscopy normal | BAL, sterile | ARDS | Methylprednisolone, Cyclosporine | Favorable (within 3 d) |

AOSD = adult-onset Still disease, ARDS = acute respiratory distress syndrome, BAL = bronchoalveolar lavage, CMV = cytomegalovirus, CT = computed tomography, CXR = chest radiography, DLCO = diffusing capacity of the lung for carbon monoxide, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity (% of predicted), HRCT = high-resolution computed tomography, ILD = interstitial lung disease, ILD = interstitial lung disease, KDO = kilocalorie/day, NA = not available, NP = not performed, NSAID = nonsteroidal anti-inflammatory drug, NSIP = nonspecific interstitial pneumonia, PEEP = positive end-expiratory pressure, PFT = pulmonary function test, PLI = parenchymal lung involvement, PMN = polymorphonuclear cell, reHLH = reactive hemophagocytic lymphohistiocytosis, RLF = restrictive lung function, SLB = surgical lung biopsy, TSLB = transbronchial biopsy, UP = usual interstitial pneumonia, VC = vital capacity.
### Table 2
Characteristics of AOSD in patients with lung involvement.

| Case | First author | Age at AOSD onset, yr | Sex | Yamaguchi and/or Faustel criteria | AOSD clinical symptoms | WBC, mm⁻¹ | PMN, mm⁻¹ | Serum ferritin, μg/L (GF%) | AOSD outcome | Other complications/concomitant reHLH |
|------|--------------|----------------------|-----|----------------------------------|------------------------|-----------|-----------|---------------------------|--------------|--------------------------------------|
| 1    | This series  | 47                   | M   | Both fulfilled                    | Fever, polyarthritis, sore throat, lymphadenopathy, pleurisy, pericarditis | 25,000     | 22,500    | 473 (19)                  | Polymyotic    | Tamponade                           |
| 2    | This series  | 61                   | M   | Fautrel fulfilled                 | Fever, polyarthritis   | 5,500     | 3,430     | 1,432 (2)                  | Polymyotic    | reHLH                               |
| 3    | This series  | 42                   | M   | Both fulfilled                    | Fever, arthralgia, lymphadenopathy | 18,000     | 15,480    | 19,000 (5)                 | Monocyclic    | Myocarditis                         |
| 4    | Corbett [30] | 19                   | F   | Both fulfilled                    | Fever, polyarthritis   | 26,500     | 21,000    | NA                        | Polymyotic    | No                                   |
| 5    | Cantor [31] | 35                   | M   | Both fulfilled                    | Fever, polyarthritis   | 16,500     | 12,000    | 2,000 (2)                  | Polymyotic    | No                                   |
| 6    | Yao [32]     | 42                   | F   | Both fulfilled                    | Fever, arthralgia, lymphadenopathy | 18,000     | 15,480    | 19,000 (5)                 | Monocyclic    | Myocarditis                         |
| 7    | Oikonomou [33] | 25                  | F   | Both fulfilled                    | Fever, polyarthritis   | 18,000     | 15,480    | 19,000 (5)                 | Monocyclic    | Myocarditis                         |
| 8    | Hirasawa [34] | 14                | F   | Both fulfilled                    | Fever, polyarthritis   | 18,000     | 15,480    | 19,000 (5)                 | Monocyclic    | Myocarditis                         |
| 9    | Ueda [35]    | 67                   | M   | Both fulfilled                    | Fever, arthralgia, lymphadenopathy | 21,000     | 18,000    | 1,893                     | Monocyclic    | No                                   |
| 10   | Nara [36]    | 21                   | M   | Both fulfilled                    | Fever, polyarthritis   | 18,000     | 15,480    | 19,000 (5)                 | Monocyclic    | No                                   |
| 11   | Su [37]      | 5                    | M   | Both fulfilled                    | Fever, polyarthritis   | 18,000     | 15,480    | 19,000 (5)                 | Monocyclic    | No                                   |
| 12   | Sah [38]     | 3                    | M   | Both fulfilled                    | Fever, polyarthritis   | 18,000     | 15,480    | 19,000 (5)                 | Monocyclic    | No                                   |
| 13   | Ibn Yacoub [40] | 22           | F   | Both fulfilled                    | Fever, polyarthritis   | 18,000     | 15,480    | 19,000 (5)                 | Monocyclic    | No                                   |
| 14   | Ak [41]      | 24                   | M   | Both fulfilled                    | Fever, polyarthritis   | 18,000     | 15,480    | 19,000 (5)                 | Monocyclic    | No                                   |
| 15   | Iglesias [42] | 9                 | F   | Both fulfilled                    | Fever, polyarthritis   | 18,000     | 15,480    | 19,000 (5)                 | Monocyclic    | No                                   |
| 16   | Pedersen [43] | 39              | M   | Both fulfilled                    | Fever, polyarthritis   | 18,000     | 15,480    | 19,000 (5)                 | Monocyclic    | No                                   |
| 17   | Sato [44]    | 32                   | F   | Both fulfilled                    | Fever, polyarthritis   | 18,000     | 15,480    | 19,000 (5)                 | Monocyclic    | No                                   |
| 18   | Acosta [45]  | 20                   | F   | Both fulfilled                    | Fever, polyarthritis   | 18,000     | 15,480    | 19,000 (5)                 | Monocyclic    | No                                   |
| 19   | Stoica [46]  | 9 (SOJA in remission until 29) | F   | Both fulfilled                    | Fever, polyarthritis   | 18,000     | 15,480    | 19,000 (5)                 | Monocyclic    | No                                   |
| 20   | Biron (2005) | 43                  | M   | Both fulfilled                    | Fever, polyarthritis, rash, pleurisy, pericarditis, ELE (hepatitis) | 18,000     | 15,480    | 19,000 (5)                 | Monocyclic    | No                                   |

AOSD = adult-onset Still disease, DIC = diffuse intravascular coagulation, ELE = elevated liver enzyme, F = female, GF = gynecostatic ferritin, M = male, MOF = multiple organ failure, NA = not available, PLI = parenchymal lung involvement, PMN = polymorphonuclear cell, reHLH = reactive hemophagocytic lymphoid lymphoma, SIRS = systemic inflammatory response syndrome, SOJA = systemic onset of juvenile idiopathic arthritis, WBC = white blood cell count.

* Because these cases are reported ones, follow-up data are unavailable and the monocyclic onset of AOSD is not sure.
Laboratory data

| Clinical data       | AOSD + PLI group | Non-ARDS PLI group | ARDS group | Control group |
|---------------------|------------------|--------------------|------------|---------------|
| N                   | 30               | 18                 | 12         | 54            |
| Female patients     | 16 (53)          | 9 (50)             | 7 (58)     | 30 (56)       |
| Male patients       | 14 (47)          | 9 (50)             | 5 (42)     | 24 (44)       |
| Age at AOSD onset   | 34.3±18          | 33.5±17.8          | 35±19.4    | 37.8±15.9     |
| Fever               | 30 (100)         | 18 (100)           | 12 (100)   | 52 (96)       |
| Arthralgias         | 14 (47)          | 8 (44)             | 6 (50)     | 51 (94)       |
| Arthritis           | 12 (40)          | 9 (50)             | 3 (21)     | 24 (44)       |
| Rash                | 22 (73)          | 11 (61)            | 11 (92)    | 42 (78)       |
| Sore throat         | 18 (60)          | 12 (67)            | 6 (50)     | 42 (78)       |
| Lymphadenopathy     | 10 (33)*         | 7 (39)             | 3 (25)     | 31 (57)       |
| Plaunoy             | 8 (27)           | 4 (22)             | 4 (33)     | 8 (15)        |
| Pericarditis        | 8 (27)           | 5 (28)             | 3 (25)     | 9 (17)        |
| Systemic AOSD       | 18/21 (86)       | 11/14 (79)         | 77 (100)   | 40 (74)       |
| Monocyclic AOSD     | 7/21 (33)        | 4/14 (29)          | 3/7        | 16 (30)       |
| Polycyclic AOSD     | 11/21 (52)       | 7/14 (50)          | 4/7        | 24 (44)       |
| Chronic AOSD        | 3/21 (15)        | 3/14 (21)          | 0          | 14 (26)       |
| Other complications | 13 (43)          | 6 (33)             | 7 (58)*    | 16 (30)       |
| Proven reHLH        | 3 (10)           | 2 (11)             | 1 (8)      | 8 (15)        |
| Deaths              | 2 (7)            | 0 (0)              | 2 (17)     | 0 (0)         |
| Laboratory data     |                  |                    |            |               |
| Leukocytes          | 19,507±7,089*    | 19,017±7,964*      | 20,241±5,806* | 13,607±6,848 |
| Polymorphonuclears  | 17,050±6,765*    | 15,651±9,246*      | 16,701±4,432* | 11,668±5,888 |
| Eosinophils         |                  | 5 (28)*            | 8 (67)     | 31 (57)       |
| Serum ferritin, µg/L| 37,363±101,027*  | 47,662±133,261*    | 13,864±13,056* | 8,877±20,364 |

Data are expressed as either n (%) or value±SD. AOSD = adult-onset Still disease, ARDS = acute respiratory distress syndrome, PLI = parenchymal lung involvement, reHLH = reactive hemophagocytic lymphohistiocytosis, SIRS = systemic inflammatory response syndrome.

* Significant difference versus the control group.
† 7 patients among the 12 in the ARDS group suffered from other AOSD complications: severe SIRS (n=6), multiple organ failure (n=2), and diffuse intravascular coagulation (n=3).

All 12 patients were treated with corticosteroids, 2 received additional intravenous polyvalent immunoglobulins, 1 received cyclophosphamide, and 1 cyclosporine. The outcome of ARDS was quickly favorable in 10 cases (often in <1 week), but 2 patients died: the first from ARDS and the second from an associated reHLH at 12 and 6 weeks from AOSD onset.

Regarding the AOSD pattern, ARDS occurred only in the systemic pattern. The complications associated with AOSD were frequent: 8 out of 12 patients had at least 1. The most common complications were severe systemic inflammation response syndrome (n=6), multiple organ failure (n=2), and diffuse intravascular coagulation (n=2). reHLH was confirmed in only 1 patient with ARDS; however, reHLH was probably underreported because, in cases 19, 23, and 26, the necessary investigations were not carried out.

3.4. Comparison between the AOSD + PLI group and the AOSD control group

The age at AOSD onset was lower in the AOSD + PLI group than in the control group. The distribution of PLI was equivalent between men and women. The frequencies of various AOSD symptoms were the same in the AOSD + PLI group and in the control group, although lymphadenopathy seemed less prevalent in the AOSD + PLI group and sore throat less frequently reported in the ARDS group. As mentioned above, ARDS occurred only during systemic AOSD, whereas other PLIs could also occur during chronic articular AOSD. The occurrence of other complications of AOSD was more frequent in the ARDS group than in the control group (Table 3).

The examination of the laboratory data showed that the leukocyte count, the polymorphonuclear cell count, and the serum ferritin level were higher in the AOSD + PLI group than in the controls (Table 3).

4. Discussion

A PLI may be associated with AOSD; this occurred in nearly 5% of AOSD cases in our series, which is more frequent than in the general population. Two main kinds of PLI may be distinguished during AOSD: 1 with ARDS and another with other PLIs.

ARDS seems to be an early complication of systemic AOSD because it occurred during the first year of the disease in all but 2 cases (83%). It is the leading cause of death in AOSD-related PLI: it was associated with death in 2 patients (17%). Furthermore, ARDS was frequently associated with other organ failures or other systemic complications of AOSD. In most cases, corticosteroids provided favorable outcomes, this treatment being the standard of care in systemic and complicated AOSD.[53] In fact, ARDS has been shown to be caused by an inflammatory injury to the lungs and corticosteroids remain of interest in noninfectious ARDS.

In the light of recent advances in the understanding of the pathophysiology of AOSD, underlying reHLH could be underreported.[3,13,16,27] Identifying this entity should be a key element in ARDS control in case of corticosteroid failure (the case of the 2 patients who died) because this speeds switching the treatment to cyclosporine, etoposide, or biological agents.[58] Data on the IL-1 receptor antagonist (anakinra) and the humanized anti-IL-6 receptor antibody (tocilizumab) are scarce in life-threatening conditions.

[54,55]

[58]
complications of AOSD. However, the rapid use of anakinra may be of value in this situation.159–162 In a recent case series, 2 out of 5 patients with reHLH in AOSD had lung involvement. In agreement with the literature, the present study suggests that treatment with a combination of IL-1 receptor antagonist, a calcineurin inhibitor, and a systemic glucocorticoid may lead to favorable outcomes.163

The non-ARDS PLI could occur during systemic AOSD, more rarely during chronic rheumatic AOSD, but at any time during the course of the disease. The clinical features were nonspecific and the basal crackles were reported in one-quarter of cases. Imaging revealed most often lower lobe interstitial and alveolar infiltrates together with pleural effusion. As in connective tissue disease—especially in dermatomyositis—2 cases of pneumo- mediastinum were reported.

PFTs were not frequently performed. They often showed a persistent restrictive lung function in 3 cases without chronic respiratory failure; this highlights the interest of performing these tests in monitoring the disease and assessing the sequelae. The differential cell count of the BAL had most often a neutrophilic profile, but this is not specific to AOSD+PLI. This finding should raise the concern about a pulmonary infection before starting corticosteroids. Imaging and histological data allow dividing AOSD-related non-ARDS PLI into 2 groups: a predominant airway involvement (bronchiolitis and bronchitis) and a predominant interstitial lung disease (nonspecific interstitial pneumonia, organizing pneumonia, or unclassifiable interstitial pneumonia).

In non-ARDS PLI cases, corticosteroids were often efficient. Only a minority of patients kept pulmonary function sequelae. Thus, the present results do not support the use of methotrexate or intravenous immunoglobulins during the acute phase of non-ARDS PLI.

Comparing the AOSD+PLI group and the control group, the age at AOSD onset was lower in the former, but this finding should be interpreted with caution because some patients with PLI found in the literature presented a first flare of AOSD during childhood, whereas this could not be documented in the retrospective cohort because it included only patients >16 years old.

The present study has the biases inherent to its retrospective design, mainly data missingness (local cases) and publication bias. Only a minority of patients kept pulmonary function sequelae. In the prospective cohort, PFTs were not frequently performed. They often showed a persistent restrictive lung function in 3 cases without chronic respiratory failure; this highlights the interest of performing these tests in monitoring the disease and assessing the sequelae. The differential cell count of the BAL had most often a neutrophilic profile, but this is not specific to AOSD+PLI. This finding should raise the concern about a pulmonary infection before starting corticosteroids. Imaging and histological data allow dividing AOSD-related non-ARDS PLI into 2 groups: a predominant airway involvement (bronchiolitis and bronchitis) and a predominant interstitial lung disease (nonspecific interstitial pneumonia, organizing pneumonia, or unclassifiable interstitial pneumonia).

5. Conclusion

A specific PLI may occur in about 5% of AOSD cases. ARDS is the most severe pulmonary manifestation in the systemic pattern of AOSD; its occurrence should orient toward an underlying reHLH because it was responsible for all AOSD+PLI-attributable deaths in this study. Non-ARDS–PLI includes bronchiolitis and nonspecific interstitial lung diseases; its prognosis is favorable. In most of AOSD+PLI cases, prednisone is efficient and the outcome is favorable. In refractory or life-threatening PLI cases, biological treatments such as anakinra or tocilizumab are presumably of interest but this remains to be proven.

References

[1] Bywaters EG. Still’s disease in the adult. Ann Rheum Dis 1971;30:121–33.
[2] Narula N, Narula T, Abriel A. Seizing the clinical presentation in adult onset Still’s disease. An extensive literature review. Autoimmun Rev 2015;14:472–7.
[3] Gerfaud-Valentin M, Jamilloux Y, Iwaz J, et al. Adult-onset Still’s disease. Autoimmun Rev 2014;13:708–22.
[4] Faure B, Le Moél G, Saint-Marcoux B, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease. J Rheumatol 2000;27:322–9.
[5] Maria ATJ, Le Quellec A, Jorgensen C, et al. Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 2014;13:1149–59.
[6] Hor A, Toh M-L, Coppée B, et al. Reactive hemophagocytic syndrome in adult-still disease: clinical features and long-term outcome: a case–control study of 8 patients. Medicine (Baltimore) 2010;89:37–46.
[7] Bae C-B, Jung J-Y, Kim H-A, et al. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patients. Medicine (Baltimore) 2013;92:e451.
[8] Gerfaud-Valentin M, Seve P, Iwaz J, et al. Myocarditis in adult-onset Still disease. Medicine (Baltimore) 2014;93:280–9.
[9] Cagatay Y, Güll A, Cagatay A, et al. Adult-onset Still’s disease. Int J Clin Pract 2009;63:1003–5.
[10] Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 1991;70:118–36.
[11] Gerfaud-Valentin M, Maxoort-Bouchl D, Hot A, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore) 2014;93:91–9.
[12] Yamaguchi M, Ohira A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol 1992;19:424–30.
[13] Faurel B, Zing F, Golmard J-L, et al. Proposal for a new set of classification criteria for adult-onset Still disease. Medicine (Baltimore) 2002;81:194–200.
[14] Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733–48.
[15] Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307:2526–33.
[16] Troum O, Mohler J, Koss M, et al. Pulmonary abnormalities in adult-onset Still’s disease. Arthritis Rheum 1985;28:578.
[17] Jottrand M, Lienart F, Decaux G. Infrequent manifestations of Still’s disease in the adult. About 2 cases. Rev Med Brux 1985;6:704.
[18] Gips CJ, Foord C, Lee HA, et al. Disseminated intravascular coagulation in adult-onset Still’s disease with neurological, respiratory and hepatic sequelae. Br J Hosp Med 1993;50:278–9.
[19] Manganeli P, Fioretta P, Zuccoli P. Adult-onset Still’s disease with respiratory distress syndrome, polyserositis and disseminated intravascular coagulation: a case with a fatal outcome. Clin Exp Rheumatol 2003;21:139.
[20] Shimomoto H, Imazumi K, Mizoguchi K, et al. A case of adult Still’s disease with severe pulmonary complications. Nihon Kyoubu Shikkan Gakkai Zasshi 1989;27:1092–9.
[22] Yokoyama M, Suwa A, Shinozawa T, et al. A case of adult onset Still’s disease complicated with adult respiratory distress syndrome and disseminated intravascular coagulation. Jpn J Clin Immunol 1995;18:207–14.

[23] Suyama T, Yokoyama K. Interstitial pneumonitis detected by bronchoalveolar lavage and transbronchial lung biopsy in adult-onset Still’s disease. Jpn Respir Soc 1998;36:545–50.

[24] Mito K, Yamakami Y, Mizunoe S, et al. A case of adult-onset Still’s disease complicated with acute respiratory distress syndrome, Jpn Respir Soc 2002;40:894–9.

[25] Mitou J, Krouzeček A, Radej J, et al. 24-Year old male with fever, multi-organ dysfunction and fast progressing ARDS. Vnitr Lek 2009;55:991–4.

[26] Hirohata S, Kamoshita H, Taketani T, et al. Adult Still’s disease complicated with adult respiratory distress. Arch Intern Med 1986;146:2409–10.

[27] Nakae Y, Ichikawa N, Ichida H, et al. Interstitial pneumonia in adult-onset Still’s disease. Clin Exp Rheumatol 2007;25:343–4.

[28] Guignard S, Dien G, Dougdados M. Severe systemic inflammatory response syndrome in a patient with adult onset Still’s disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol 2007;25:758–9.

[29] Shinohara T, Hidaka T, Matsuki Y, et al. Calcinosi cutis and intestinal pseudodiverticulosis in a patient with adult onset Still’s disease associated with recurrent relapses of disordered coagulopathy. Intern Med 1999;38:516–20.

[30] Ibn Yacoub Y, Amine B, Laatiris A, et al. Bilateral low lobar atelectasis in a young woman with adult-onset Still’s disease. Rheumatol Int 2010;30:1639–41.

[31] Corbett AJ, Zizic TM, Stevens MB. Adult-onset Still’s disease complicated with adult respiratory distress syndrome. Jpn Respir Soc 1998;36:545

[32] Van Hoeyweghen RJ, De Clerck LS, Van Offel JF, et al. Interstitial lung disease complicated with acute respiratory distress syndrome and adult respiratory distress syndrome. Jpn Respir Soc 2002;40:894–9.

[33] Sato H, Yokoe I, Nishio S, et al. A case of adult onset Still’s disease complicated with a cause of ARDS and acute respiratory failure. Scand J Rheumatol 2002;31:181–3.

[34] Higayama H, Koike R, Nagasaka K, et al. Two cases of acute respiratory distress syndrome resulting from adult-onset Still’s disease. Mod Rheumatol 2003;13:76–80.

[35] Biron C, Chambellan A, Agard C, et al. Acute respiratory failure revealing adult-onset Still’s disease: diagnostic value of low glycosylated ferritin level. Clin Rheumatol 2006;25:766–8.

[36] Dua AB, Manadan AM, Case JP. Adult onset Still’s disease presenting with acute respiratory distress syndrome: case report and review of the literature. Open Rheumatol J 2013;7:123–8.

[37] Jamilouix Y, Gerfaud-Valentin M, Henry T, et al. Treatment of adult-onset Still’s disease: a review. Ther Clin Risk Manag 2015;11:133–43.

[38] Fonte RG, Fishier CJ, Clemmer TP, et al. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest 1987;92:1032–6.

[39] Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006;354:1671–84.

[40] Jamilouix Y, Gerfaud-Valentin M, Martinon F, et al. Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart. Immunol Res 2015;61:53–62.

[41] Gerfaud-Valentin M, Sève P, Hot A, et al. Pathophysiology, subtypes, and treatments of adult-onset Still’s disease: an update. Rev Med Intern 2015;36:319–27.

[42] Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet 2014;383:1503–16.

[43] Lequerré T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008;67:302–8.

[44] Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease: a case-series study. Arthritis Res Ther 2011;13:R91.

[45] Nordström D, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol 2012;39:2008–11.

[46] Giampietro C, Ridel E, Lequerré T, et al. Anakinra in adult-onset Still’s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res 2013;65:822–6.

[47] 2014, ACR/ARHP, annual meeting abstract, supplement. Arthritis Rheumatol 2014;66:S1–402.

[48] Mazzucco M, Del Forno M, Branca B, et al. Bilateral empyema caused by adult-onset Still’s disease: clinical and radiological presentation. Vnitr Lek 2008;64:1507–10.

[49] Kimura Y, Weiss JE, Haroldson KL, et al. Pulmonary hypertension and adult-onsetStill’s disease. Chest 1987;92:939–40.

[50] Raynaud Е, Mohindra K, B builds E, et al. Pulmonary interstitial fibrosis in adult onset Still’s disease: a case report. Rev Med Interne 1997;18:575–8.

[51] Watanabe Y, Hori K, Tashiro Y, et al. Pulmonary involvement in adult-onset Still’s disease: a review. Ther Clin Risk Manag 2015;11:338–44.

[52] Ak O, Ozor S, Cag Y, et al. An adult onset Still’s disease mimicking pneumococcal pneumonia. Rheumatol Int 2012;32:2539–41.

[53] Fujii K, Kitamura Y, Osugi Y, et al. A case of adult-onset Still’s disease complicated with atypical pulmonary disease. Rheumatol Int 2011;31:239–42.

[54] Ghasi A, Pal RB, Das SK, et al. An unusual presentation of adult onset Still’s disease. Med J Malaysia 2012;67:352–3.

[55] Pedersen JE. ARDS—associated with adult Still’s disease. Intensive Care Med 1991;17:372.

[56] Paccalin M, Chapon C, Roblot P, et al. Severe pulmonary manifestation in adult-onset Still’s disease. Rev Med Internne 1997;18:575–7.

[57] Iglesias J, Sathiraraj S, Marik PE. Severe systemic inflammatory response syndrome with shock and ARDS resulting from Still’s disease: clinical response with high-dose pulse methylprednisolone therapy. Chest 2014;145:1173–80.

[58] Carron PL, Sercin S, Plane P, et al. Adult-onset Still’s disease, a rare cause of acute respiratory distress. Rev Med Interne 2000;21:1133–4.

[59] Storos G, Cohen RJ, Roosfield LJ. Adult Still’s disease and respiratory failure in a 74 year old woman. Postgrad Med J 2002;78:97–8.

[60] Suleiman M, Wolfvoet E, Boulman N, et al. Adult onset Still’s disease as a cause of ARDS and acute respiratory failure. Scand J Rheumatol 2002;31:181–3.

[61] Chen C-H, Chen H-A, Wang H-P, et al. Pulmonary arterial hypertension in autosomemutation disease: a review of 19 cases from a medical center in northern Taiwan. J Microbiol Immunol Infect 2006;39:162–8.